Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06859801 · ClinicalTrials.gov registry record
A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy
A clinical trial of Bone Cancer Metastatic, sponsored by Society of Interventional Oncology.
- Recruiting
- Registry status
- 120
- Enrollment target
- 6
- Study locations
NCT06859801: Recruiting study of Bone Cancer Metastatic, sponsored by Society of Interventional Oncology.
NCT06859801 is a study of Bone Cancer Metastatic that is actively recruiting participants, run by Society of Interventional Oncology. The registered enrollment target is 120 participants. The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06859801, a study of Bone Cancer Metastatic, is actively recruiting participants, sponsored by Society of Interventional Oncology.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objective of this study is to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilization, etc.) in patients treated with both percutaneous ablation and palliative radiation therapy (RT).
Primary Outcome
Combined partial and complete pain response rate using the Brief Pain Inventory (BPI), worst pain 24-hour recall, at 3 months following percutaneous ablation and palliative RT as defined by International Consensus on Palliative Radiotherapy Endpoints in clinical trials (ICPRE). • Partial response is defined as pain reduction of 2 or more at the treated site on a scale of 0 to 10 scale without analgesic increase, or analgesic reduction of 25% or more from Baseline without an increase in pain. •
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DEVICE Percutaneous Ablation
Study Locations (6)
Georgia
- Emory University Hospital - Atlanta
- Northside Hospital - Atlanta
California
- University of California San Diego Moores Cancer Center - San Diego
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University - St Louis
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2027-07-31 |
What NCT06859801 shows while recruiting
NCT06859801 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Bone Cancer Metastatic appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT06859801 lists 6 locations in 5 states (Georgia, California, Minnesota).
Frequently Asked Questions
What is clinical trial NCT06859801 about?
NCT06859801 is a clinical study titled "A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy". The objective of this study is to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilization, etc.) in patients treated with both percutaneous ablation and palliative radiation therapy (RT).
What is the current status of trial NCT06859801?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2025-10-23. Estimated completion is 2027-07-31.
What conditions does trial NCT06859801 study?
This clinical trial studies the following conditions: Bone Cancer Metastatic.
What interventions are being tested in trial NCT06859801?
The interventions under investigation include: Radiation Therapy (RADIATION), Percutaneous Ablation (DEVICE).
Who is sponsoring clinical trial NCT06859801?
This trial is sponsored by Society of Interventional Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06859801 being conducted?
This trial has 6 study locations across California, Georgia, Minnesota, Missouri, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI